# A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC

> **NCT01263002** · PHASE4 · COMPLETED · sponsor: **Bukwang Pharmaceutical** · enrollment: 33 (estimated)

## Conditions studied

- Hepatitis B Associated Hepatocellular Carcinoma

## Interventions

- **DRUG:** clevudine, Adefovir

## Key facts

- **NCT ID:** NCT01263002
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2013-01
- **Final completion:** 2013-09
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2014-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263002, "A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01263002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*